Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/148793COMPARTIR / EXPORTAR:
 SHARE
 CORE
BASE
|
|
| Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
| Título: | Eculizumab in secondary atypical haemolytic uraemic syndrome |
Autor: | Cavero, Teresa; Arjona, Emilia CSIC ORCID ; Rodríguez de Córdoba, Santiago ; Praga, Manuel | Palabras clave: | Atypical hemolytic uremic syndrome Complement activation Eculizumab Thrombotic microangiopathies |
Fecha de publicación: | mar-2017 | Editor: | Oxford University Press | Citación: | Nephrol Dial Transplant (2017) 32: 466–474 (2017) | Resumen: | Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab. Methods. We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization of platelet count (>150 109/L) and haemoglobin, disappearance of all the markers of microangiopathichaemolytic anaemia (MAHA), and improvement of renal function,with a 25% reduction of serum creatinine from the onset of eculizumab administration. Results. Twenty-nine patients with secondary aHUS (15 druginduced,8 associated with systemic diseases, 2 with postpartum,2 with cancer-related, 1 associated with acute humoral rejectionand 1 with intestinal lymphangiectasia) were included in this study. The reason to initiate eculizumab treatment was worsening of renal function and persistence of TMA despite treatment of the TMA cause and plasmapheresis. All patients showed severe MAHA and renal function impairment (14 requiring dialysis) prior to eculizumab treatment and 11 presented severe extrarenal manifestations. A rapid resolution of the TMA was observed in 20 patients (68%), 15 of them showing a _>50% serum creatinine reduction at the last follow-up. Comprehensive genetic and molecular studies in 22 patients identified complement pathogenic variants in only 2 patients. With these two exceptions, eculizumab was discontinued, after a median of 8 weeks of treatment, without the occurrence of aHUS relapses. Conclusion. Short treatment with eculizumab can result in a rapid improvement of patients with secondary aHUS in whom TMA has persisted and renal function worsened despite treatment of the TMA-inducing condition. |
Descripción: | 9 p.-1 fig.-7 tab. Cavero, Teresa et al. | Versión del editor: | http://dx.doi.org/10.1093/ndt/gfw453 | URI: | http://hdl.handle.net/10261/148793 | DOI: | 10.1093/ndt/gfw453 | ISSN: | 0931-0509 | E-ISSN: | 1460-2385 |
| Aparece en las colecciones: | (CIB) Artículos |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| Nephrol. Dial Transplant 2017.pdf | Artículo principal | 888,76 kB | Adobe PDF |  Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
55
checked on 02-abr-2024
SCOPUSTM
Citations
110
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
95
checked on 25-feb-2024
Page view(s)
444
checked on 23-abr-2024
Download(s)
268
checked on 23-abr-2024
